The novel phorbol ester receptor ␤2-chimaerin is a Rac-GAP protein possessing a single copy of the C1 domain, a 50-amino acid motif initially identified in protein kinase C (PKC) isozymes that is involved in phorbol ester and diacylglycerol binding. We have previously shown that, like PKCs, ␤2-chimaerin binds phorbol esters with high affinity in a phospholipid-dependent manner (Caloca, M. J., Fernandez, M. N., Lewin, N. E., Ching, D., Modali, R., Blumberg, P. M., and Kazanietz, M. G. (1997) J. Biol. Chem. 272, 26488 -26496). In this paper we report that like PKC isozymes, ␤2-chimaerin is translocated by phorbol esters from the cytosolic to particulate fraction. Phorbol esters also induce translocation of ␣1 (n)-and ␤1-chimaerins, suggesting common regulatory mechanisms for all chimaerin isoforms. The subcellular redistribution of ␤2-chimaerin by phorbol esters is entirely dependent on the C1 domain, as revealed by deletional analysis and site-directed mutagenesis. Interestingly, ␤2-chimaerin translocates to the Golgi apparatus after phorbol ester treatment, as revealed by co-staining with the Golgi marker BODIPY-TR-ceramide. Structure relationship analysis of translocation using a series of PKC ligands revealed substantial differences between translocation of ␤2-chimaerin and PKC␣. Strikingly, the mezerein analog thymeleatoxin is not able to translocate ␤2-chimaerin, although it very efficiently translocates PKC␣. Phorbol esters also promote the association of ␤2-chimaerin with Rac in cells. These data suggest that chimaerins can be positionally regulated by phorbol esters and that each phorbol ester receptor class has distinct pharmacological properties and targeting mechanisms. The identification of selective ligands for each phorbol ester receptor class represents an important step in dissecting their specific cellular functions.
The phorbol ester tumor promoters are the most common tools for the activation of protein kinase C (PKC) 1 in biological systems. These natural compounds exert a variety of effects in cells, which have been largely attributed to the calcium-dependent classical PKCs (cPKC␣, ␤I, ␤II, and ␥) or calciumindependent novel PKCs (nPKC␦, ⑀, , and ). Unlike cPKCs and nPKCs, the third class of PKC isozymes or atypical PKCs (aPKC and PKC/) is phorbol ester-unresponsive. Phorbol esters also target PKC (PKD), a kinase related to PKC that has unique substrate specificity and regulation (1) (2) (3) (4) . The heterogeneity in the phorbol ester responses is probably related to the multiple phorbol ester receptors present in each cell type. An additional level of complexity in the phorbol ester responses is conferred by the unique pharmacological profile of each phorbol ester analog. In fact, ligands for PKCs not only include the typical diterpene phorbol esters but also a large number of unrelated structural analogs such as nonphorbol ester diterpenes (e.g. mezereins, octahydromezerein, and thymeleatoxin), macrocyclic lactones (e.g. bryostatins), and indole alkaloids (e.g. indolactams and teleocidins). The differential effects of phorbol ester analogs in cellular models suggest unique modes of interaction with different phorbol ester receptor classes and may explain the heterogeneous properties of the ligands (4 -7). One of the important novel concepts that has emerged in the past few years is that PKC isozymes are not the only receptors for the phorbol esters and related derivatives. In fact three novel families of phorbol ester receptors unrelated to PKCs have been isolated. These novel phorbol ester receptors, which lack a kinase domain in their structure, include the chimaerin isoforms, Caenorhabditis elegans Unc-13 and its mammalian homologs (Munc13 isoforms), and RasGRP. These proteins have in common a single copy of the C1 domain, a 50/51-amino acid motif that is duplicated in tandem in cPKC and nPKCs, which is the binding site for the phorbol esters and diacylglycerol (DAG) in these PKCs (4, 6, 7) . It has recently been reported that chimaerins, Unc-13, and RasGRP bind phorbol esters and related analogs with high affinity in vitro, thereby suggesting that a single copy of the C1 domain is sufficient to confer binding responsiveness. In all cases phorbol ester binding is phospholipid-dependent, and acidic phospholipids are the most efficient cofactors for reconstitution of binding (8 -11) . The identification of these "nonkinase" phorbol ester receptors suggests that phorbol esters and related analogs may regulate cellular pathways independently of the activation of PKC isozymes.
Chimaerins are a novel family of phorbol ester receptors with Rac GTPase-activating protein (GAP) activity and therefore accelerate the hydrolysis of GTP to GDP leading to Rac inactivation. Chimaerins comprise at least four isozymes (␣1-or n-, ␣2-, ␤1-, and ␤2-chimaerins) that are alternative spliced variants from the ␣-and ␤-chimaerin genes (14 -16) . The C1 domain in chimaerin isozymes has ϳ40% homology with those of PKC isozymes. Using the radioligand [ 3 H]phorbol 12,13-dibutyrate, we have reported that ␤2-chimaerin is a high affinity receptor for phorbol esters in vitro (8) . Competition assays revealed that different ligands have unique patterns of recognition for different phorbol ester receptors. In fact, although DAGs and indolactams have similar affinities for PKCs and ␤2-chimaerin, thymeleatoxin (a mezerein analog) has ϳ60 times less affinity for ␤2-chimaerin (8) . Therefore, it is likely that specific residues within individual C1 domains are critical for conferring binding specificity. Limited information is available on the ligand binding properties of these novel phorbol ester receptors. The regulation, localization, and function of the chimaerins are largely unexplored.
One of the hallmarks for the activation of cPKCs and nPKCs by phorbol esters is their change in subcellular localization or "translocation." Translocation of PKC isozymes is a complex process that not only involves lipid-protein interactions mediated by the C1 domain and other motifs, but it is also dictated by protein-protein associations that may play a key role in determining function specificity for each PKC isozyme (12, 13) . The aim of this study is to investigate whether chimaerins are subject to subcellular redistribution or translocation by phorbol ester analogs. The results presented in this paper show that chimaerins are subject to subcellular translocation by phorbol ester derivatives. Using a series of deletion mutants of ␤2-chimaerin, we determined that translocation is entirely dependent on the ligand binding to the C1 domain. Interestingly, we found that upon stimulation with different analogs, ␤2-chimaerin translocates to the Golgi apparatus. These data indicate that the chimaerin family of phorbol ester receptors has unique ligand recognition properties and suggests that phorbol esters have the potential to regulate additional targets in addition to PKC isozymes.
EXPERIMENTAL PROCEDURES
Materials-PMA, 4␣-PMA, thymeleatoxin, (Ϫ)-octylindolactam V, 12-deoxyphorbol 13-phenyacetate, and GF 109203X were purchased from LC Laboratories (Woburn, MA). Bryostatin 1 was a kind gift from Dr. Peter M. Blumberg (NCI, National Institutes of Health). BODIPY-TR-ceramide was obtained from Molecular Probes, Inc. (Eugene, OR). Cell culture reagents and media were obtained from Life Technologies, Inc.
Cell Culture-COS-1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere.
Generation of ␤2-Chimaerin Expression Vectors-A 1.4-kilobase XhoI-MluI fragment comprising the full-length ␤2-chimaerin was ligated into the mammalian expression vector pCR3⑀ to generate pCR3⑀-␤2-chimaerin, as we have previously described elsewhere (8) . To generate a GFP construct for ␤2-chimaerin (pEGFP-␤2-chimaerin), a 1.4-kilobase EcoRI-EcoRI fragment was isolated from pCRII-␤2-chimaerin (8) and subcloned in-frame into the GFP plasmid pEGFP-C3 (CLON-TECH; Ref. 17) . Deletion mutants of ␤2-chimaerin were generated by PCR using from pEGFP-␤2-chimaerin as a template. The following oligonucleotides were used (EcoRI and SalI restriction sites are underlined): CATGAATTCATGCGTCTCCTCTCC and AGATGTCGACGGC-AGTCATTGGGAAC (amino acids 1-262), for pEGFP-␤2-N-C1; GAGG-AATTCCACAACTTTAAGGTCC and AGATGTCGACGGCAGTCATTG-GGAAC (amino acids 213-262), for pEGFP-␤2-C1; GAGGAATTCCAC-AACTTTAAGGTCC and GCGCGTCGACATTAGAATAAAACGTCT-TCG (amino acids 213-466), for pEGFP-␤2-C1-GAP. The PCR products were ligated into pCRII using the TA cloning kit (Invitrogen). The corresponding EcoRI and SalI fragments were isolated and subcloned into the GFP plasmid pEGFP-C2 (CLONTECH). The construct pEGFP-␤2-GAP was generated by PCR from pACG2T-␤2-chimaerin (8) using the following oligonucleotides: CGCACGCGTGAATAAAACGTCT-TCGTTTTCTATTAA and AGCCTCCAGATGGTGGTAGACATATG-CATTCGGGAA. The PCR product was ligated into pCRII, and a fragment comprising the GAP domain (amino acids 291-466) was isolated by digestion with EcoRI and ligated in frame into pEGFP-C2 to generate pEGFP-␤2-GAP.
To construct pEGFP-␣1-chimaerin, the full-length cDNA for ␣1-chimaerin (18) was used as a template, and EcoRI and XhoI sites were created by PCR (restriction sites underlined), using the following oligonucleotides: CCGGAATTCATGCCATCCAAAGAGTCTTGGTC and CCGCTCGAGCTAAAATAAAATGTCTTC. The insert was ligated in frame into pEGFP-C2. ␤1-Chimaerin was isolated from human testis cDNA (CLONTECH) by PCR using the following oligonucleotides: GT-CAGGCTCGAGGGATCCATGCTTTGCACGTCTCCCGTC (XhoI site underlined) and CGCACGCTGAAACAGAACATCTTCGTTTTCTATT-AA. The ␤1-chimaerin cDNA was subcloned into pCRII vector, and a XhoI-EcoRI fragment from that plasmid was subcloned into pEGFP-C3 to generate pEGFP-␤1-chimaerin. Generation of the mutant C246A-␤2-chimaerin and the plasmid pEGFP-C246A-␤2-chimaerin was described elsewhere (17) . In all cases, constructs were sequenced by the dideoxy chain termination method.
Expression of ␤2-Chimaerin in COS-1 Cells and Subcellular Fractionation-Mammalian expression vectors for chimaerins or deletion mutants were transfected into COS-1 cells in 6-well plates using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's protocol. 48 h after transfection, cells were treated with different concentrations of phorbol ester analogs. Experiments were performed in the presence of the PKC inhibitor GF 109203X (5 M), added 30 min before and during the incubation with the phorbol ester analogs, as we have previously described (8) .
Cells were harvested into lysis buffer (50 mM Tris-HCl, pH 7.4, 5 mM EGTA, 5 g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 5 g/ml leupeptin, 5 g/ml aprotinin, and 1 g/ml pepstatin A) and lysed by sonication. Separation of cytosolic (soluble) and particulate fractions was performed by ultracentrifugation as described previously (8, 17) . Equal amounts of protein (10 g) for each fraction were subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes that were immunostained with different antibodies. The following antibodies were used: anti-PKC␣ antibody (1:3,000; Upstate Biotechnology Inc., Lake Placid, NY), anti-␤2-chimaerin antibody (1:1,000), and anti-GFP antibody (1:25,000). The intensity of the bands was determined by densitometry using a Scanner Control, version 1.00 (Molecular Dynamics, Inc., Sunnyvale, CA). Densitometric analysis was performed under conditions that yielded a linear response.
Visualization of GFP-␤2-Chimaerin Translocation by Fluorescent Microscopy-COS-1 cells were transfected with the GFP expression vectors using FuGENE (Roche Molecular Biochemicals), according to the manufacturer's protocol. After 48 h, cells were treated with the phorbol ester analogs and fixed with 3.7% formaldehyde. Photomicrographs were taken with an Olympus fluorescent microscope.
For staining of the Golgi network, COS-1 cells transfected with the GFP-expression vectors were incubated with BODIPY TR ceramide (2 g/ml) for 30 min at 37°C. After incubation, cells were washed twice with PBS and then treated with phorbol esters for 30 min. Cells were then washed and fixed with 3.7% formaldehyde. Slides were mounted using Vectashield and viewed with a Bio-Rad MRC-1024ES laser scanning confocal microscope. The confocal images were processed using Confocal Assistant TM , version 4.02. All the images shown are individual middle sections of projected Z series mounting.
Modeling Studies-A newly developed q jumping molecular dynamics simulation method, which has been used to successfully predict the PKC-ligand receptor complex (19) , was used to predict the binding model of thymeleatoxin in complex with ␤2-chimaerin. The major advantage of this program is its ability to include both the ligand and receptor flexibility in the docking simulation. The q jumping algorithm has been implemented in the CHARMM program, as described previously (19, 20) . The q jumping procedure was carried out using a CHARMM script. The CHARMM force field (21) was used to describe the structure of the receptor, and all the necessary parameters for thymeleatoxin were generated by using the QUANTA program (Molecular Simulations Inc., San Diego, CA).
The three-dimensional structure of ␤2-chimaerin C1 domain was modeled based upon the x-ray structure of PKC␦ C1b, as described previously (17, 22) . Starting from the phorbol 13-acetate structure in the x-ray crystal data (22), the initial conformation of thymeleatoxin was generated by QUANTA. All the appropriate hydrogen atoms were added to the ligand and minimized. In the docking simulation, the ligand was allowed to be fully flexible, and all the side chains of the residues 8 -12 and 20 -27, which form the ligand binding site in ␤2-chimaerin, were allowed to be flexible; everything else in the receptor was fixed in our docking simulation. Then, the MD simulations described above were carried out in vacuum, using the following q jumping parameters: q ϭ 1.02-1.03, ⑀ ϭ 800 and P J ϭ 0.1. The q jumping MD simulations were carried out at T ϭ 300 K, using the constant temperature algorithm of Berendsen et al. (23) . The SHAKE algorithm (24) was used to fix all the bonds containing hydrogen with a time step of 1 fs. For energy evaluations, a distance-dependent dielectric model was employed with the nonbonding interactions truncated at 8 Å. Finally nuclear Overhauser effect constraints consisting of a central atom of the ligand, and each ␣-carbon atom in the ␤2-chimaerin residues 10 and 24 was introduced to prevent the ligand from escaping from the binding site completely. With the MD protocol, we performed several independent MD runs for 1-2 ns, and the binding mode was determined from the lowest minimum energy conformation from each of the MD trajectories. Then, the resulting complex structures were further refined by a minimization consisting of 5000 steps of adopted Newton-Raphson method.
Determination of Rac-GAP Activity-To determine GTPase activity of ␤2-chimaerin, recombinant purified Rac was first incubated at 30°C for 10 min with [␥-32 P]GTP (60 Ci/nmol; Amersham Pharmacia Biotech) in loading buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.1 mM dithiothreitol, and 0.5 M MgCl 2 ). The loading reaction was stopped by the addition of MgCl 2 (final concentration, 10 mM). Purified ␤2-chimaerin (expressed in Sf9 cells) was then incubated with loaded Rac in reaction buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM dithiothreitol, 10 mM MgCl 2 , 1 mg/ml bovine serum albumin, 1 mM GTP) at 15°C, and Rac GTPase activity was determined in filters by measuring the reduction in Rac-bound radioactivity (25) . To determine the effect of phospholipids on GAP activity, purified ␤2-chimaerin was preincubated with 100 g/ml of phospholipids (variable proportions of phosphatidylserine, and the remaining lipid is neutral phosphatidylcholine) for 45 min at 30°C in reaction buffer, prior to adding the loaded Rac. Experiments were performed in duplicate. In general, duplicate determinations differed by Ͻ10%. Expression and purification of recombinant ␤2-chimaerin from Sf9 cells is described elsewhere (8) .
Association of ␤2-Chimaerin and Rac-COS-1 cells were co-transfected with pCR3⑀-␤2-chimaerin and pEBG-Rac (a mammalian expression vector for GST-Rac) or pEBG (empty vector for expression of GST alone). pEBG vectors were a kind gift of Dr. Margaret M. Chou (University of Pennsylvania School of Medicine). 48 h after transfection cells were treated with GF 109203X (5 M) for 30 min and then for 1 h with PMA (3 M). After treatment, cells were harvested into lysis buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 5 mM MgCl 2 , 0.1 mM dithiothreitol, 5 g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 5 g/ml leupeptin, 5 g/ml aprotinin, and 1 g/ml pepstatin A), and the lysates were then incubated with glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) for 2 h at 4°C. Beads were extensively washed with lysis buffer, resuspended in Laemmli's sample buffer, and boiled. Samples were subjected to 12% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and then probed with anti-␤2-chimaerin antibody (1:1000). Aliquots of total lysates were also probed with an anti-␤2-chimaerin antibody (1:1000) and an anti-GST antibody (Amersham Pharmacia Biotech; 1:1,000).
RESULTS

Translocation of ␤2-Chimaerin by Phorbol Ester Derivatives-
We have previously shown that ␤2-chimaerin, a RacGAP protein, is a high affinity phorbol ester receptor. Our previous work revealed that ␤2-chimaerin binds [ 3 H]phorbol 12,13-dibutyrate in a phospholipid-dependent fashion with an affinity that is in the same range as cPKCs and nPKCs (8) . Cells were transfected with the mammalian expression vector pCR3⑀-␤2-chimaerin, and high levels of expression of ␤2-chimaerins were observed 48 h later, as judged by Western blot analysis and by assessing phorbol ester binding levels (8) . To assess the effects of phorbol esters on the subcellular distribution of ␤2-chimaerin, cells were treated with PMA and then subjected to subcellular fractionation. The levels of ␤2-chimaerin in soluble (cytosolic) and particulate fraction were then determined by Western blot. These experiments were carried out in the presence of the PKC inhibitor GF 109203X (5 M) to rule out any involvement of PKCs in the effect of phorbol esters, as we have previously described (8, 17) . Fig. 1 shows that PMA induced translocation of ␤2-chimaerin from the soluble to the particulate fraction in a dose-dependent manner. A GFP fusion construct for ␤2-chimaerin was also generated and responds to PMA in a similar fashion as the nonfused construct, suggesting that, as previously described for PKC isozymes (26 -29) , the GFP tag does not affect responsiveness to phorbol esters. As expected, nonfused GFP protein was unresponsive to PMA.
Phorbol ester derivatives and related analogs have unique binding properties for discrete PKC isozymes, and recent studies have shown that different derivatives have differential properties for translocating PKC isozymes (28, 29) . Our previous in vitro studies on structure-activity analysis revealed striking differences in binding potency between ␤2-chimaerin and PKC isozymes. In fact, although phorbol esters and 12-deoxyphorbol esters have ϳ10-fold lower affinity for ␤2-chimaerin than for PKC␣, indole alkaloids (indolactams) have similar binding potency, and mezerein derivatives such as the tumor promoter thymeleatoxin show ϳ60-fold less affinity for ␤2-chimaerin (8). To explore the structure-activity for translo- cation of ␤2-chimaerin, we investigated the effect of four different analogs on the subcellular redistribution of this novel receptor and compared it with PKC␣ (Fig. 2) . The macrocyclic lactone bryostatin 1, an analog with an atypical spectrum of biological responses compared with the typical phorbol esters, was the most potent agent at inducing translocation of ␤2-chimaerin. The ED 50 for translocation is ϳ30 nM. Bryostatin 1 is somewhat more potent in translocating PKC␣ (ED 50 ϳ3 nM). The 12-deoxyphorbol ester derivative 12-deoxyphorbol 13-phenyacetate and the indole alkaloid (Ϫ)-octylindolactam V both induced translocation of ␤2-chimaerin. Despite the similar potency in vitro for binding recognition, 2 (Ϫ)-octylindolactam V was very poor at inducing translocation of ␤2-chimaerin when compared with PKC␣. Strikingly, the mezerein derivative thymeleatoxin was totally ineffective at inducing translocation of ␤2-chimaerin even at a concentration of 10 M. On the other hand, thymeleatoxin fully translocated PKC␣ at a concentration of 10 nM, suggesting that this derivative is a selective agent for translocation of PKC.
Studies with Deletion Mutants of ␤2-Chimaerin: Translocation Dependence on the C1 Domain-The C1 domains in PKCs are the binding sites for phorbol esters and related derivatives and are essential for mediating the subcellular redistribution of PKCs. To ascertain whether the C1 domain in ␤2-chimaerin mediates its translocation after phorbol ester treatment, we constructed a series of deletion mutants for ␤2-chimaerin in pEGFP vector. The following constructs were generated (Fig.  3A) : GFP-␤2-N-C1 (from N terminus to C1-domain), GFP-␤2-C1 (C1 domain alone), GFP-␤2-C1-GAP (from C1 domain to C terminus), and GFP-␤2-GAP (GAP domain alone). Cells were transfected with each of these constructs and subsequently treated with PMA. Western blot analysis of soluble and particulate fractions after subcellular fractionation revealed that PMA induced the translocation of GFP-␤2-C1 and GFP-␤2-C1-GAP from soluble to particulate fraction, as observed with the full-length ␤2-chimaerin (Fig. 3B) . On the other hand, no changes in subcellular localization were observed after deletion of the C1 domain, as revealed by the absence of translocation of GFP-␤2-GAP after PMA treatment. Unexpectedly, a deleted version of ␤2-chimaerin expressing only the N-terminal region and C1 domain (GFP-␤2-N-C1) was found at the particulate fraction even in the absence of PMA treatment. The involvement of the C1 domain in translocation was confirmed by site-directed mutagenesis of the C1 domain. A point mutant of ␤2-chimaerin in which Cys in position 246 was replaced by Ala was generated and expressed as a GFP fusion protein (GFP-C246A-␤2-chimaerin). Position 246 corresponds to the third Cys in the C1 domain, which is essential for the coordination of Zn 2ϩ , as determined in structural studies in C1 domains of PKCs (22) . In a previous study we have determined that this ␤2-chimaerin mutant does not bind phorbol esters (17) . In agreement with our results with the deletion mutants, GFP-C246A-␤2-chimaerin does not translocate in response to PMA. All together, these results unambiguously indicate that the C1 domain mediates the translocation of ␤2-chimaerin.
Translocation of Different Chimaerin Isoforms by PMA-All chimaerin isoforms have in common a single C1 domain. The homology between the C1 domains of ␣-and ␤-chimaerins is ϳ94%. Like ␤2-chimaerin, ␣1-chimaerin (n-chimaerin) is a high affinity phorbol ester receptor in vitro, and it binds [ 3 H]phorbol 12,13-dibutyrate in a phospholipid-dependent manner with an affinity that is similar to that of PKC isozymes (18) . To evaluate whether multiple chimaerin isozymes respond to PMA, we transiently expressed ␣1-, ␤1-, and ␤2-chimaerins in COS-1 cells and monitored subcellular distribution in each case after PMA treatment. Fractionation of untreated cells revealed that 25 and 45% of the ␣1-and ␤1-chimaerin immunoreactivity was present in the soluble fraction (cytosol), compared with 85% for ␤2-chimaerin. After PMA treatment, the immunoreactivity in the soluble fraction is sub- stantially reduced in all cases (Fig. 4) . Unlike ␤2-chimaerin, an increase in the particulate fraction for ␣1-and ␤1-chimaerins was not evident, probably because most of the immunoreactivity is already present in the particulate fraction before stimulation. Remarkably, as observed with ␤2-chimaerin, thymeleatoxin did not induce any significant changes in the levels of soluble ␣1-chimaerin. Only a small fraction of ␤1-chimaerin was translocated by thymeleatoxin when compared with PMA. Therefore, thymeleatoxin is a much more potent agent in translocating PKC␣ than chimaerin isoforms, as we have demonstrated in Fig. 2 .
Molecular Modeling of Thymeleatoxin Binding to PKC␣ C1b and ␤2-Chimaerin C1 Domains-The reduced binding affinity of ␤2-chimaerin for thymeleatoxin and the marked differences in translocation between PKC␣ and ␤2-chimaerin suggest that each receptor may interact differently with this ligand. We therefore decided to perform a molecular modeling analysis of the C1 domains of PKC␣ and ␤2-chimaerin in complex with thymeleatoxin. For the purposes of this study, we use the C1b domain of PKC␣ (Fig. 5 ). X-ray crystallographic studies of PKC␦ C1b domain and our previous molecular modeling and site-directed mutagenesis analysis have clearly demonstrated that the binding of ligands to PKC C1 domains is governed by two important interactions, namely hydrogen bonding and hydrophobic interactions (22, 30) . Thymeleatoxin forms an identical hydrogen bond network with PKC␣ C1b and ␤2-chimaerin, suggesting that the selectivity between PKC␣ and ␤2-chimaerin for thymeleatoxin is not due to different hydrogen bonding interactions. In the predicted binding models, thymeleatoxin is in close contact with a number of hydrophobic residues, including residues at positions 11, 20, 22, and 24. Although the residues at positions 11 and 24 (Pro and Leu) are conserved between PKC␣ C1b and ␤2-chimaerin C1 domains, the residues at positions 20 and 22 are Leu in PKC␣ C1b and Phe in ␤2-chimaerin. The residue at position 22 is Tyr in PKC␣ C1b but is replaced by Trp in ␤2-chimaerin. Importantly, a Leu residue is conserved at position 20 among all the PKC C1b domains. Thus, these different hydrophobic residues at positions 20 and 22 in PKC␣ C1b and ␤2-chimaerin may explain differences in binding recognition for thymeleatoxin.
Furthermore, although the residue at position 9 is hydrophilic in nature in PKC C1b domains, a positively charged Arg residue is present in position 9 of ␤2-chimaerin. Based upon the x-ray structure of PKC␦ C1b in complex with phorbol 13-acetate, it was proposed that a primary mechanism of PKC translocation and activation upon ligand binding is the transformation of a predominant hydrophilic surface to a hydrophobic surface, thus allowing the effective insertion into the membrane (22) . The presence of a positively charged Arg residue at position 9 in ␤2-chimaerin makes the surface less hydrophobic upon ligand binding and may make ␤2-chimaerin intrinsically less capable of translocation than PKCs, as supported by our current results. Thus, the inability of thymeleatoxin to translocate ␤2-chimaerin may be due to the combination of the weaker binding affinity for thymeleatoxin binding to the C1 domain of ␤2-chimaerin (8) and the intrinsic weaker ability of ␤2-chimaerin to translocate to the membrane.
Localization Studies Using GFP-tagged ␤2-Chimaerin and Its Mutants-PKC isozymes translocate to different intracellular compartments upon activation with phorbol esters and related derivatives. Evaluation of subcellular localization of GFP-␤2-chimaerin by fluorescence microscopy revealed that this novel phorbol ester receptor was distributed in the cytoplasm. No nuclear staining was observed. Upon PMA stimulation, a significant fraction of GFP-␤2-chimaerin distributed to a perinuclear region. We also observed faint plasma membrane staining upon PMA treatment (Figs. 6A and 7) . No translocation was observed upon treatment of cells with the inactive PMA isomer 4␣-PMA (Fig. 6A) . Similar results were observed in immunofluoresence studies with ␤2-chimaerin nonfused to GFP using an anti-␤2-chimaerin antibody (data not shown).
Recent studies by the Blumberg lab (28, 29) have shown a distinct pattern of redistribution of PKC isozymes depending on the phorbol ester analog used, suggesting that the PKC activator plays a key role in determining intracellular localization. We decided to evaluate whether a similar mechanism takes place for ␤2-chimaerin. Experiments using bryostatin 1, the 12-deoxyphorbol ester 12-deoxyphorbol 13-phenyacetate, and (Ϫ)-octylindolactam V revealed similar perinuclear localization of ␤2-chimaerin in all cases (Fig. 6A ). In agreement with our Western blot studies, thymeleatoxin was unable to translocate GFP-␤2-chimaerin to the perinuclear region, thereby confirming the lack of an effect for this derivative.
In the next set of experiments we evaluated the localization of the ␤2-chimaerin mutants previously described. In agreement with the fractionation analysis (Fig. 3) , the point mutant C246A-␤2-chimaerin retained its cytoplasmatic localization after PMA treatment (Fig. 6B) . Likewise, the ␤2-chimaerin GAP domain was unresponsive to PMA. The presence of a functional C1 domain confers responsiveness, as shown with GFP-␤2-C1-GAP. Interestingly, the mutant expressing the N-terminal region of ␤2-chimaerin (GFP-␤2-N-C1) was localized to the perinuclear region either in the absence or presence of PMA treatment. This is in agreement with the Western blot results showing that this mutant was fully localized to the particulate fraction even in the absence of phorbol ester treatment (Fig. 3) .
To determine the nature of the perinuclear compartment to which ␤2-chimaerin translocated after phorbol ester treatment, cells were treated with BODIPY TR ceramide, a red fluorescent probe that specifically labeled the Golgi network. This probe has been previously used to determine the Golgi localization of PKC␦ after activation (27) . We evaluated colocalization of GFP-␤2-chimaerin before and after PMA treatment. As illustrated in Fig. 8 , GFP-␤2-chimaerin shows some degree of co-localization with the Golgi marker in the absence of PMA treatment. However, a marked increase in co-localization in the perinuclear region was observed after PMA treatment, as judged by superposition of the images. The mutant GFP-␤2-N-C1, which was localized to the perinuclear region even in the absence of PMA, co-localized with BODIPY TR ceramide without and with PMA treatment (data not shown). Our results demonstrate that PMA induces the translocation of ␤2-chimaerin to the Golgi network.
Rac-GAP Activity of ␤2-Chimaerin-It has previously been demonstrated that ␣1-chimaerin has RacGAP activity, and, therefore, it accelerates the hydrolysis of GTP from Rac (31) . As shown in Fig. 8A , ␤2-chimaerin also accelerates the hydrolysis of GTP from Rac in a concentration-dependent manner. No effect of ␤2-chimaerin on Cdc42 or RhoA was observed (data not shown). 4 Interestingly, when we performed similar assays in the presence of phospholipid vesicles, we observed a marked increase in GAP activity of ␤2-chimaerin (1 ng/l) as the concentration of phosphatidylserine in the vesicles increases (Fig.  8B) . Phosphatidyserine did not induce any changes in GTP hydrolysis in the absence of ␤2-chimaerin (data not shown). A FIG. 4 . Multiple chimaerin isozymes are translocated by PMA. COS-1 cells were transfected with pEGFP, pEGFP-␣1-chimaerin, pEGFP-␤1-chimaerin, or pEGFP-␤2-chimaerin. After 48 h cells were treated with PMA (P) or thymeleatoxin (T) (1 M, 1 h) in the presence of GF109203X (5 M). After subcellular fractionation by ultracentrifugation, soluble and particulate fractions were subjected to Western blot analysis using either an anti-GFP or anti-PKC␣ antibody. The molecular masses of GFP-␣1-chimaerin, GFP-␤1-chimaerin, and GFP-␤2-chimaerin are 61, 59, and 78 kDa, respectively. Two additional experiments gave similar experiments. C, Control.
FIG. 5. Docking of thymeleatoxin to the PKC␣ C1b and ␤2-chimaerin C1 domains.
similar effect was observed with other acidic phospholipds, such as phosphatidic acid, but not with neutral phospholipids, such as phosphatidylethanolamine. 4 Therefore, the Rac-GAP activity of chimaerins is regulated by its association to lipids.
PMA Promotes the Association of ␤2-Chimaerin to Rac-We
hypothesize that regulation of ␤2-chimaerin by phorbol esters may promote its association to Rac. A similar model has been documented for PKC isozymes, where phorbol esters promote translocation of PKCs and their association to PKC regulatory proteins and substrates (4) . To evaluate the association of Rac with ␤2-chimaerin, COS-1 cells were co-transfected with expression vectors for GST-Rac (or GST alone) and ␤2-chimaerin. GST-Rac (or GST) from cell extracts was then bound to glutathione-Sepharose 4B beads, and the presence of ␤2-chimaerin in the beads was evaluated by Western blot with an anti-␤2-chimaerin antibody (Fig. 9) . Association of Rac with ␤2-chimaerin was not detected in nonstimulated cells. In contrast, treatment of COS-1 cells with PMA for 1 h markedly increased the amount of ␤2-chimaerin associated to GST-Rac. No association to GST alone was found either in the absence or presence of PMA. Therefore, phorbol esters promote the association of ␤2-chimaerin with its effector Rac in cells.
DISCUSSION
In this study we have demonstrated that chimaerin isoforms, like cPKCs and nPKCs, are positionally regulated by phorbol esters. Translocation of chimaerins by phorbol esters is dependent on the chimaerin C1 domain and independent of PKC activation. We have previously demonstrated that these Rac-GAP proteins bind phorbol esters and DAG with low nanomolar affinity (8, 17) . Like PKCs, phorbol ester binding to chimaerins is dependent on phospholipids as cofactors, which suggests that association to membranes may be crucial for regulating its activity and/or association to targets. In that regard, it was previously shown that the GAP activity of ␣1-chimaerin is activated by acidic phospholipids such as phosphatidylserine (31) . In this paper we have observed a similar activation of ␤2-chimaerin by this acidic phospholipid. Therefore, as described for cPKCs and nPKCs, the association of ␤2-chimaerin to membrane phospholipids regulates its activity. In preliminary experiments we observed that phorbol esters do not promote RacGAP activity of ␤2-chimaerin in vitro and that they do not change the phosphatidylserine requirement for GAP activity. 4 Although a small degree of activation of RacGAP activity by phorbol esters has been reported for ␣1-chimaerin (31), our results suggest that phorbol esters are responsible for targeting ␤2-chimaerin to membranes rather than triggering its allosteric activation. Our observation that ␤2-chimaerin associates with Rac upon phorbol ester treatment suggests that translocation of ␤2-chimaerin may be a key event in the regulation of Rac activity. We have also observed that ␤2-chimaerin does not affect GTP hydrolysis from Cdc42 or RhoA, and in addition it inhibits Rac-GTP levels upon stimulation of the EGF receptor in COS-1 cells, an indication that ␤2-chimaerin has RacGAP activity not only in vitro but also in cells. 4 We have identified the C1 domain in chimaerins as the minimum domain required for phorbol ester binding and subcellular redistribution in cells. It is therefore clear that a single C1 domain is sufficient for binding of phorbol esters. These results support those from previous experiments using single C1 domains of PKCs, which show that this 50-amino acid domain is sufficient for ligand binding (30, 32, 33) . Moreover, experiments using a single C1 domain of PKC␥ fused to GFP have shown that this domain was capable of translocating to membranes (35) . The notion that a single C1 domain is sufficient to confer translocation is supported by studies showing that functional inactivation of a single C1 domain in PKC␣ or PKC␦ renders mutant PKCs that are still able to translocate upon phorbol ester stimulation (36, 37) . However, these mutants having a single functional C1 domain require higher phorbol ester concentration for translocation, as observed with ␤2-chimaerin. Therefore, two C1 domains may account for the full responsiveness for PKC translocation by phorbol esters. Our studies do not rule out the possibility that the reduced sensitivity of ␤2-chimaerin for translocation compared with PKCs is related to the absence of other domains present in PKC that are involved in protein-lipid and/or protein-protein interaction, such as the C2 domain.
It is interesting that ␤2-chimaerin associates with a perinuclear compartment upon phorbol ester activation. Co-staining with a specific Golgi marker reveals a Golgi localization for ␤2-chimaerin. It has been previously reported that PKC␦ and PKC⑀ translocate to the Golgi network upon treatment with phorbol esters or DAGs (28, 38 -41) . Translocation of PKC⑀ to the Golgi is mediated by its C1 domains (38) and involves the association with the coatomer protein ␤Ј-COP, a Golgi protein that acts as an intracellular receptor for PKC⑀ (39) . Interestingly, the novel phorbol ester receptor Munc13 also translocates from the cytosol to the Golgi apparatus after phorbol ester stimulation (42) . In support of our localization studies, it was reported that ␣1-chimaerin regulates Golgi stability during interphase (43) . Others have also described the requirement of a PKC-like molecule without phosphorylating activity for the production of post-Golgi vesicles (44) . Association of PKCs to other organelles including mitochondria, lysosomes, and endo- plasmic reticulum has also been reported (45) (46) (47) . In analogy with the models proposed for PKC isozymes, translocation of chimaerins may involve protein-protein interaction mechanisms. In fact, we have recently isolated a chimaerin interacting protein (Tmp21 or p23) using the yeast two-hybrid system. 5 This protein is expressed in the Golgi apparatus and endoplasmic reticulum. Remarkably, the association of ␤2-chimaerin and p23 in cells is markedly enhanced by phorbol ester treatment, suggesting that mechanisms of protein-protein interaction similar as those described for PKC isozymes can dictate the intracellular localization of chimaerins. It may be possible that, upon activation, a conformational change in ␤2-chimaerin occurs that exposes the protein-protein interacting sites, as also described for PKC isozymes. The domain in chimaerins interacting with p23 is in the N-terminal region, 5 which may explain the constitutive association of the mutant ␤2-N-C1 to the perinuclear region. It is important to mention that a large pool of intracellular Rac, the target for chimaerins, is located in a perinuclear region and kept in an inactive state (48) . An attractive hypothesis is that chimaerins may play a role in the maintenance of this small GTP-binding protein in an inactive, GDP-bound state at the perinuclear compartment. These important issues are currently being investigated in our laboratory.
Our experiments using different ligands show important differences in their potencies for translocating ␤2-chimaerin. We have previously reported that PKC ligands have a unique pattern for binding to this RacGAP protein (8) . Remarkably, each receptor class (i.e. PKC isozymes, Unc-13, RasGRP, and chimaerins) interacts differently with phorbol esters and related analogs (6, 8, 9, 11, 49) . Clearly, specific residues within the individual C1 domains confer unique properties to each receptor class. This is not surprising, because marked differences in ligand selectivity have been shown for individual C1 domains. Potent ligands for one C1 domain may be either weak ligands or may not bind at all to other C1 domains, such as the C1 domains of PKC, Vav, or Raf (6, 50, 51) . These striking differences have been reported even for the C1a and C1b domain of a single PKC isozyme, such as PKC␣, PKC␦, or PKC, providing strong evidence that C1 domains are nonequivalent (6) . Structural and biochemical studies with individual C1 domains have confirmed that these marked differences for ligand recognition exist, as described for unrelated ligands such as indolactams, DAGs, and certain phorbol ester analogs (17, 34, 50, 52) . In fact, a detailed structure-activity analysis of ␤2-chimaerin revealed unique binding properties for this novel phorbol ester receptor. The 60-fold difference in binding affinity for thymeleatoxin between PKC␣ and ␤2-chimaerin is the highest reported so far for two individual phorbol ester receptors. Although mutagenesis studies within the ␤2-chimaerin C1 domain have yet to be done, our modeling analysis with thymeleatoxin has revealed distinct binding recognition for PKC␣ and ␤2-chimaerin. It is also remarkable that thymeleatoxin is very potent in translocating PKC␣ but poorly translocates chimaerin isoforms. To our knowledge, this is the first example of a selective ligand for phorbol ester receptors, a finding that will be valuable for dissecting the biological functions of each receptor class.
In summary, the chimaerin isoforms represent a novel class of phorbol ester receptors that are subject to subcellular translocation by phorbol esters and related analogs through their C1 domain. The unique pharmacological properties and distinct localization of each receptor highlights the complexity of phorbol ester pharmacology and DAG signaling, as well as makes questionable the use of phorbol esters as specific ligands for PKC isozymes. The elucidation of the cellular functions of the novel chimaerin receptors will benefit from the rationale design of specific pharmacological agents.
